Additionally, interleukin-2 (IL-2), a multifunctional cytokine is known to activate T cells in TME of thyroid cancer by upregulating Human Leukocyte antigen (HLA) class I molecule expression and subsequent tumor antigen presentation [9]. This evidence concerns the gene IL2 and thyroid gland carcinoma.